Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CORE-OCU: radium-223 plus enzalutamide in metastatic castration-resistant prostate cancer
jRCTs051180124Completed
- Sponsor
- Bayer
- Start
- Nov 2017
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of radium-223 dichloride and enzalutamide in castration-resistant prostate cancer (CRPC), sponsored by Bayer. Started Nov 2017; status: completed.
02
Drugs
radium-223 dichlorideenzalutamide
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on jRCTs051180124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180124.